Figure 5From: The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1Anti-myeloma effects of drugs against gp96 knockdown cell line. (A) PU-H71. (B) 17-AAG. (C) 17-DMAG. (D) Dexamethasone. (E) Bortezomib. (F) Melphalan. (G) Doxorubicin. (H) Thalidomide. All drug treatment was for 24 hours. * p < 0.05.Back to article page